BIO Bio-Rad Laboratories Inc

Price (delayed)

$337.99

Market cap

$9.64B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$21.82

Enterprise value

$10.64B

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, ...

Highlights
The EPS has soared by 82% YoY
The net income has soared by 82% YoY
The equity has contracted by 9% YoY but it has grown by 3.9% from the previous quarter
Bio-Rad Laboratories's gross profit has decreased by 9% YoY and by 2.1% from the previous quarter
The revenue has contracted by 4.7% YoY

Key stats

What are the main financial stats of BIO
Market
Shares outstanding
28.52M
Market cap
$9.64B
Enterprise value
$10.64B
Valuations
Price to book (P/B)
1.13
Price to sales (P/S)
3.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.98
Earnings
Revenue
$2.67B
EBIT
-$800.67M
EBITDA
-$800.67M
Free cash flow
$218.47M
Per share
EPS
-$21.82
Free cash flow per share
$7.48
Book value per share
$299.92
Revenue per share
$91.45
TBVPS
$395.94
Balance sheet
Total assets
$12.3B
Total liabilities
$3.56B
Debt
$1.41B
Equity
$8.74B
Working capital
$2.53B
Liquidity
Debt to equity
0.16
Current ratio
5.83
Quick ratio
4.02
Net debt/EBITDA
-1.25
Margins
EBITDA margin
-30%
Gross margin
53.4%
Net margin
-23.9%
Operating margin
12.6%
Efficiency
Return on assets
-5.1%
Return on equity
-7.2%
Return on invested capital
-6.6%
Return on capital employed
-6.8%
Return on sales
-30%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
-0.14%
1 week
-0.74%
1 month
7.21%
1 year
-30.6%
YTD
4.68%
QTD
4.68%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.67B
Gross profit
$1.43B
Operating income
$337.8M
Net income
-$637.32M
Gross margin
53.4%
Net margin
-23.9%
The net income has soared by 82% YoY
The net margin has surged by 82% year-on-year
BIO's operating income is down by 30% year-on-year and by 6% since the previous quarter
BIO's operating margin is down by 27% year-on-year and by 5% since the previous quarter

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
P/E
N/A
P/B
1.13
P/S
3.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.98
The EPS has soared by 82% YoY
BIO's P/B is 29% below its 5-year quarterly average of 1.6 and 13% below its last 4 quarters average of 1.3
The equity has contracted by 9% YoY but it has grown by 3.9% from the previous quarter
The stock's price to sales (P/S) is 30% less than its 5-year quarterly average of 5.3 and 10% less than its last 4 quarters average of 4.1
The revenue has contracted by 4.7% YoY

Efficiency

How efficient is Bio-Rad Laboratories business performance
Bio-Rad Laboratories's ROA has soared by 82% YoY
The company's return on invested capital has surged by 82% YoY
The ROE has soared by 82% year-on-year
The ROS has soared by 82% YoY

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The total assets has declined by 9% year-on-year but it has increased by 3.4% since the previous quarter
BIO's total liabilities is down by 8% year-on-year but it is up by 2.2% since the previous quarter
The debt is 84% smaller than the equity
Bio-Rad Laboratories's debt to equity has increased by 14% YoY but it has decreased by 6% from the previous quarter
The equity has contracted by 9% YoY but it has grown by 3.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.